Is TVRD or TENX more profitable?

Tenax Therapeutics' return on equity of -61.54% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -145.40% -91.11% Tenax Therapeutics N/A -61.54% -57.42%

Does the media refer more to TVRD or TENX?

In the previous week, Tenax Therapeutics had 1 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 3 mentions for Tenax Therapeutics and 2 mentions for Tvardi Therapeutics. Tenax Therapeutics' average media sentiment score of 0.99 beat Tvardi Therapeutics' score of 0.19 indicating that Tenax Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tvardi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tenax Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ATHE or TVRD?

Alterity Therapeutics has higher earnings, but lower revenue than Tvardi Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$15.88M N/A N/A Tvardi Therapeutics $7.14M 2.15 -$18.21M -$2.79 N/A

Is ATHE or TVRD more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A Tvardi Therapeutics N/A -145.40% -91.11%

Does the media prefer ATHE or TVRD?

In the previous week, Alterity Therapeutics had 1 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 3 mentions for Alterity Therapeutics and 2 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.19 beat Alterity Therapeutics' score of -0.24 indicating that Tvardi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Tvardi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ZYBT or TVRD?

Tvardi Therapeutics has a consensus target price of $18.00, indicating a potential upside of 1,465.22%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tvardi Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Which has better valuation and earnings, ZYBT or TVRD?

Zhengye Biotechnology has higher revenue and earnings than Tvardi Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 3.53 -$9.98M N/A N/A Tvardi Therapeutics $7.14M 2.15 -$18.21M -$2.79 N/A

Is ZYBT or TVRD more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A Tvardi Therapeutics N/A -145.40% -91.11%

Is TLPH or TVRD more profitable?

Talphera's return on equity of -87.28% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Talphera N/A -87.28% -51.36% Tvardi Therapeutics N/A -145.40% -91.11%

Does the media prefer TLPH or TVRD?

In the previous week, Tvardi Therapeutics had 1 more articles in the media than Talphera. MarketBeat recorded 2 mentions for Tvardi Therapeutics and 1 mentions for Talphera. Tvardi Therapeutics' average media sentiment score of 0.19 beat Talphera's score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Talphera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tvardi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is TVRD or ELOX more profitable?

Eloxx Pharmaceuticals' return on equity of 0.00% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -145.40% -91.11% Eloxx Pharmaceuticals N/A N/A N/A

Does the media favor TVRD or ELOX?

In the previous week, Eloxx Pharmaceuticals had 5 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 7 mentions for Eloxx Pharmaceuticals and 2 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.19 beat Eloxx Pharmaceuticals' score of 0.12 indicating that Tvardi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tvardi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eloxx Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Tvardi Therapeutics (TVRD) Competitors

$1.15 -0.09 (-7.26%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.18 +0.03 (+2.17%)

As of 10/2/2026 07:30 PM Eastern

Compare

TVRD vs. TENX, ATHE, ZYBT, TLPH, and ELOX

Should you buy Tvardi Therapeutics stock or one of its competitors? Tvardi Therapeutics's main competitors and comparable companies include Tenax Therapeutics (TENX), Alterity Therapeutics (ATHE), Zhengye Biotechnology (ZYBT), Talphera (TLPH), and Eloxx Pharmaceuticals (ELOX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Tvardi Therapeutics compare to Tenax Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Tvardi Therapeutics has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

Tvardi Therapeutics has higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	2.15	-$18.21M	-$2.79	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

Tenax Therapeutics' return on equity of -61.54% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-145.40%	-91.11%
Tenax Therapeutics	N/A	-61.54%	-57.42%

Tvardi Therapeutics currently has a consensus price target of $18.00, suggesting a potential upside of 1,465.22%. Tenax Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 607.07%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Tvardi Therapeutics is more favorable than Tenax Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Tenax Therapeutics	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.40

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by company insiders. Comparatively, 10.8% of Tenax Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Tenax Therapeutics had 1 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 3 mentions for Tenax Therapeutics and 2 mentions for Tvardi Therapeutics. Tenax Therapeutics' average media sentiment score of 0.99 beat Tvardi Therapeutics' score of 0.19 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tvardi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenax Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tvardi Therapeutics and Tenax Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Alterity Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Alterity Therapeutics has higher earnings, but lower revenue than Tvardi Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$15.88M	N/A	N/A
Tvardi Therapeutics	$7.14M	2.15	-$18.21M	-$2.79	N/A

2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by company insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Alterity Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 189.86%. Tvardi Therapeutics has a consensus price target of $18.00, indicating a potential upside of 1,465.22%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Alterity Therapeutics' return on equity of 0.00% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Tvardi Therapeutics	N/A	-145.40%	-91.11%

In the previous week, Alterity Therapeutics had 1 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 3 mentions for Alterity Therapeutics and 2 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.19 beat Alterity Therapeutics' score of -0.24 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alterity Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tvardi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alterity Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Summary

Tvardi Therapeutics beats Alterity Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Zhengye Biotechnology's return on equity of 0.00% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Tvardi Therapeutics	N/A	-145.40%	-91.11%

Tvardi Therapeutics has a consensus target price of $18.00, indicating a potential upside of 1,465.22%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Tvardi Therapeutics had 2 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 2 mentions for Tvardi Therapeutics and 0 mentions for Zhengye Biotechnology. Tvardi Therapeutics' average media sentiment score of 0.19 beat Zhengye Biotechnology's score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Zhengye Biotechnology	Neutral
Tvardi Therapeutics	Neutral

Zhengye Biotechnology has higher revenue and earnings than Tvardi Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	3.53	-$9.98M	N/A	N/A
Tvardi Therapeutics	$7.14M	2.15	-$18.21M	-$2.79	N/A

Zhengye Biotechnology has a beta of -2.31, suggesting that its stock price is 331% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

44.7% of Tvardi Therapeutics shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Tvardi Therapeutics beats Zhengye Biotechnology on 9 of the 14 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Talphera?

Talphera (NASDAQ:TLPH) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

Talphera has higher earnings, but lower revenue than Tvardi Therapeutics. Talphera is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	1,955.28	-$14.29M	-$0.27	N/A
Tvardi Therapeutics	$7.14M	2.15	-$18.21M	-$2.79	N/A

Talphera currently has a consensus price target of $3.00, indicating a potential upside of 165.49%. Tvardi Therapeutics has a consensus price target of $18.00, indicating a potential upside of 1,465.22%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Talphera's return on equity of -87.28% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-87.28%	-51.36%
Tvardi Therapeutics	N/A	-145.40%	-91.11%

In the previous week, Tvardi Therapeutics had 1 more articles in the media than Talphera. MarketBeat recorded 2 mentions for Tvardi Therapeutics and 1 mentions for Talphera. Tvardi Therapeutics' average media sentiment score of 0.19 beat Talphera's score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Talphera	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tvardi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

37.7% of Talphera shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 3.5% of Talphera shares are owned by company insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Talphera has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

Summary

Tvardi Therapeutics beats Talphera on 10 of the 16 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Eloxx Pharmaceuticals?

Tvardi Therapeutics (NASDAQ:TVRD) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Tvardi Therapeutics has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Eloxx Pharmaceuticals has a beta of -1960.42, suggesting that its share price is 196,142% less volatile than the broader market.

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by company insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Eloxx Pharmaceuticals' return on equity of 0.00% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-145.40%	-91.11%
Eloxx Pharmaceuticals	N/A	N/A	N/A

In the previous week, Eloxx Pharmaceuticals had 5 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 7 mentions for Eloxx Pharmaceuticals and 2 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.19 beat Eloxx Pharmaceuticals' score of 0.12 indicating that Tvardi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tvardi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eloxx Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tvardi Therapeutics currently has a consensus target price of $18.00, indicating a potential upside of 1,465.22%. Eloxx Pharmaceuticals has a consensus target price of $38.33, indicating a potential upside of 147.15%. Given Tvardi Therapeutics' higher probable upside, research analysts plainly believe Tvardi Therapeutics is more favorable than Eloxx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Eloxx Pharmaceuticals has lower revenue, but higher earnings than Tvardi Therapeutics. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	2.15	-$18.21M	-$2.79	N/A
Eloxx Pharmaceuticals	$6.36M	9.85	-$5.99M	-$1.54	N/A

Summary

Eloxx Pharmaceuticals beats Tvardi Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Tvardi Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TVRD vs. The Competition

Export

Metric	Tvardi Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.54M	$12.24B	$7.14B	$13.18B
Dividend Yield	N/A	2.64%	2.53%	16.78%
P/E Ratio	-0.41	799.70	275.97	26.04
Price / Sales	N/A	851.67	669.23	109.59
Price / Cash	N/A	82.26	77.60	51.75
Price / Book	0.52	10.46	10.93	6.31
Net Income	-$18.21M	$2.84B	$3.51B	$362.16M
7 Day Performance	-9.45%	-1.57%	-2.00%	-1.66%
1 Month Performance	-37.84%	-5.67%	-6.15%	-4.50%
1 Year Performance	-97.14%	-4.73%	7.44%	2.06%

Tvardi Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TVRD Tvardi Therapeutics	3.5877 of 5 stars	$1.15 -7.3%	$18.00 +1,465.2%	-96.9%	$16.54M	N/A	N/A	80
TENX Tenax Therapeutics	4.4143 of 5 stars	$1.81 flat	$14.00 +673.5%	-74.0%	$67.73M	N/A	N/A	16	Short Interest Decrease
ATHE Alterity Therapeutics	3.6106 of 5 stars	$3.67 flat	$10.00 +172.5%	-17.7%	$66.54M	N/A	N/A	11
ZYBT Zhengye Biotechnology	N/A	$1.31 flat	N/A	-51.4%	$61.85M	$116.36M	N/A	269
TLPH Talphera	1.5058 of 5 stars	$1.18 flat	$3.00 +154.2%	+20.1%	$61.25M	$1K	N/A	12	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TVRD) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tvardi Therapeutics (TVRD) Competitors

TVRD vs. TENX, ATHE, ZYBT, TLPH, and ELOX

How does Tvardi Therapeutics compare to Tenax Therapeutics?

Summary

How does Tvardi Therapeutics compare to Alterity Therapeutics?

Summary

How does Tvardi Therapeutics compare to Zhengye Biotechnology?

Summary

How does Tvardi Therapeutics compare to Talphera?

Summary

How does Tvardi Therapeutics compare to Eloxx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVRD vs. The Competition

Tvardi Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tvardi Therapeutics (TVRD) Competitors

TVRD vs. TENX, ATHE, ZYBT, TLPH, and ELOX

How does Tvardi Therapeutics compare to Tenax Therapeutics?

Which has more risk and volatility, TVRD or TENX?

Which has better earnings and valuation, TVRD or TENX?

Is TVRD or TENX more profitable?

Do analysts recommend TVRD or TENX?

Do insiders & institutionals hold more shares of TVRD or TENX?

Does the media refer more to TVRD or TENX?

Summary

How does Tvardi Therapeutics compare to Alterity Therapeutics?

Which has stronger earnings & valuation, ATHE or TVRD?

Do insiders and institutionals have more ownership in ATHE or TVRD?

Do analysts rate ATHE or TVRD?

Is ATHE or TVRD more profitable?

Does the media prefer ATHE or TVRD?

Which has more risk and volatility, ATHE or TVRD?

Summary

How does Tvardi Therapeutics compare to Zhengye Biotechnology?

Is ZYBT or TVRD more profitable?

Do analysts prefer ZYBT or TVRD?

Does the media prefer ZYBT or TVRD?

Which has better valuation and earnings, ZYBT or TVRD?

Which has more volatility and risk, ZYBT or TVRD?

Do insiders and institutionals believe in ZYBT or TVRD?

Summary

How does Tvardi Therapeutics compare to Talphera?

Which has higher valuation and earnings, TLPH or TVRD?

Do analysts recommend TLPH or TVRD?

Is TLPH or TVRD more profitable?

Does the media prefer TLPH or TVRD?

Do insiders and institutionals believe in TLPH or TVRD?

Which has more risk & volatility, TLPH or TVRD?

Summary

How does Tvardi Therapeutics compare to Eloxx Pharmaceuticals?

Which has more risk and volatility, TVRD or ELOX?

Do insiders and institutionals have more ownership in TVRD or ELOX?

Is TVRD or ELOX more profitable?

Does the media favor TVRD or ELOX?

Do analysts rate TVRD or ELOX?

Which has higher valuation & earnings, TVRD or ELOX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVRD vs. The Competition

Tvardi Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools